Remifentanil added to sufentanil-sevoflurane anesthesia suppresses hemodynamic and metabolic stress responses to intense surgical stimuli more effectively than high-dose sufentanil-sevoflurane alone by Ingo Bergmann et al.
Bergmann et al. BMC Anesthesiology 2015, 15:3
http://www.biomedcentral.com/1471-2253/15/3RESEARCH ARTICLE Open AccessRemifentanil added to sufentanil-sevoflurane
anesthesia suppresses hemodynamic and
metabolic stress responses to intense surgical
stimuli more effectively than high-dose
sufentanil-sevoflurane alone
Ingo Bergmann*, Torsten Szabanowski, Anselm Bräuer, Thomas A Crozier, Martin Bauer and José Maria HinzAbstract
Background: Even extremely high-doses of the potent opioid, sufentanil, cannot reliably suppress stress responses to
intense surgical stimuli such as sternotomy. The chemically related opioid remifentanil with its different pharmacokinetics
and binding affinities for delta- and kappa-opioid receptors might be more effective in attenuating these responses.
Methods: ASA I-III patients scheduled for a surgical procedure with sternotomy under balanced anesthesia (sevoflurane
and sufentanil 3 μg.kg−1 bolus, 0.017 μg.kg−1.min−1 infusion) were randomized into two groups. Patients in the study
group were supplemented with remifentanil (2 μg.kg−1 bolus, 2–7 μg.kg−1.min−1 infusion) starting ten minutes before
sternotomy. Heart rate, arterial blood pressures, cardiac index, ejection fraction, systemic vascular resistance index (SVRI),
total body oxygen uptake (VO2) and electric dermal response were measured and compared between the groups.
Results: 62 patients were studied (study group 32, control group 30). Systolic and mean arterial blood pressures, SVRI,
VO2 and skin conductance increased during sternotomy and sternal spread in the control group but not in the study
group. Systolic blood pressure increase: 7.5 ± 19 mmHg vs. -3.4 ± 8.9 (p = 0.005); VO2 increase: 31 ± 46% vs. -0.4 ± 32%;
incidence of systolic blood pressure increase greater than 15 percent: 20% vs. 3% (p = 0.035) (control vs. study group).
Conclusion: High-dose remifentanil added to sevoflurane-sufentanil anesthesia suppresses the sympathoadrenergic
response to sternotomy and sternal spread better than high-dose sufentanil alone.
Trial registration: Clinical Trial number: DRKS 00004327, August 31, 2012
Keywords: Sternotomy, Stress response, Remifentanil, Intraoperative hypertension, Oxygen uptakeBackground
Sympathoadrenergic responses to surgical trauma affect
perioperative morbidity and mortality and are particu-
larly undesirable in patients with ischemic or congestive
heart disease. Increased blood pressure and oxygen con-
sumption can cause myocardial ischemia and ultimately
worsen the patients' perioperative prognosis [1]. High
doses of opioid narcotics were shown to provide
hemodynamic stability and suppress most reactions to* Correspondence: Ingo.Bergmann@med.uni-goettingen.de
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unless otherwise stated.surgical trauma [2-5]. But even sufentanil, administered
at up to one hundred-fold the normal anesthetic dose,
cannot reliably prevent the responses to sternotomy and
sternal spread [6], a stimulus that is known to cause
myocardial ischemia [7]. The reason for this is that the
maximal effect attainable with sufentanil is insufficient.
This effect cannot be increased by administering a even
larger dose (ceiling-effect) as shown by the sigmoid
plasma concentration-response curve [8,9].
Remifentanil is chemically related to sufentanil [10],
but differs from it in several aspects. Remifentanil has an
extremely short context-sensitive half time [11] which
allows it to be administered in very high doses duringtral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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ing recovery time [10,12]. Remifentanil also has different af-
finities for cardiac kappa and delta opioid receptors [13].
These receptors are thought to mediate the cardioprotec-
tive effect reported for remifentanil [13] and could also pos-
sibly be exploited to attenuate the cardiovascular responses
that do not respond to the predominantly μ-opioid receptor
activation of sufentanil. One possible disadvantage of remi-
fentanil might be its reported link to opioid-induced hyper-
algesia [14,15].
We hypothesized that high-dose remifentanil given be-
fore and during sternotomy in addition to a balanced
high-dose sufentanil-sevoflurane anesthesia could attenu-
ate the cardiovascular and metabolic stress responses.
Methods
General
This prospective, randomized double-blinded study was
conducted with the approval of our clinical research ethics
committee (Universitätsmedizin Göttingen, Ethikkommis-
sion 14/2/11, on 29 March 2012). It was registered on Au-
gust 31, 2012 with the German registry of clinical trials
(Deutsches Register für klinische Studien (http://drks-neu.
uniklinik-freiburg.de/drks_web/navigate.do?navigationId=
trial.HTML&TRIAL_ID=DRKS00004327) under the trial
number DRKS 00004327. The participating patients gave
their written consent after having been informed by the
principal investigator, Dr. Bergmann, both orally and with
written information material.
Patients
ASA I - III patients scheduled for surgery requiring ster-
notomy for cardiac surgery were eligible for inclusion.
Exclusion criteria were emergency surgery or a pre-
operative hemoglobin concentration under 10 g dL−1.
After having given written informed consent the patients
were randomized to the control or the study group using
a computer-generated list (www.randomizer.org). All pa-
tients had a balanced anesthesia with high-dose sufenta-
nil and sevoflurane. In addition to these drugs, the
patients in the study group were given remifentanil as a
continuous infusion in the period before and during
sternotomy (see below). Two investigators (IB and TS)
performed all anesthetics.
Patient preparations
Premedication consisted of oral midazolam 7.5 mg given
on the ward 20 to 30 minutes before induction of
anesthesia. In the operating room an infusion was estab-
lished via a peripheral vein and the radial artery was cannu-
lated. We attached forehead electrodes for measuring state
entropy (S/5 monitor, GE Healthcare, Helsinki, Finland)
and palmar Ag/AgCl2 electrodes for measuring skin con-
ductance (Elektrosympathograph 1001, Ingenieurbüro Dr.Janitzki, Altenbeken, Germany [16]). After induction, a
four-lumen central venous catheter and a pulmonary artery
catheter were inserted; the latter was positioned with the
inflated balloon in wedge position. The transesophageal
echocardiography (TEE) probe was introduced and used to
assess cardiac filling volumes and measure ejection frac-
tions (fractional area change, FAC, in the transgastric mid
short-axis view).
Monitoring
Heart rate, systolic and mean arterial pressure (SAP,
MAP), pulmonary artery pressure (PAP), central venous
pressure (CVP), oxygen consumption (VO2), Surgical
Pleth Index (SPI, see below), entropy (SE and RE) and
skin conductance as an indicator of sympathetic nervous
system activity were monitored continuously and the
data stored for offline analysis by a researcher not in-
volved in data acquisition and blinded to the patient's
group. VO2 was measured by indirect calorimetry with
the integrated metabolic monitor module of the respir-
ator (Datex Ohmeda M-COVX). Plasma catecholamine
concentrations were not determined because they are
not reliable indicators of endogenous secretion in this
setting, since many patients are routinely given catechol-
amine infusions during the pre-sternotomy phase, as
was the case in the present study
Cardiac output (CO) was measured by thermodilution
after intubation, at skin incision for vein harvesting, at
sternotomy and ten minutes after sternum spreading.
Ice-cold 0.9% NaCl was used as injectate. Pulmonary ar-
tery wedge pressure (PAWP) and mixed-venous oxygen
saturation (SvO2) were also measured at these times.
Cardiac (CI) and systemic vascular resistance indexes
(SVRI) were calculated from the data. Ejection fractions
were determined before and after sternotomy. At these
time points sufficient crystalloid fluids had been infused
to correct any pre-existing hypovolemia and normalize
cardiac filling volumes in all patients.
The Surgical Pleth Index (SPI) is an indicator of the
body's response to noxious stimuli and thus indirectly of
the intensity of analgesia and was used to guide the ad-
ministration of the remifentanil and sufentanil [12,17,18].
The SPI is a dimensionless number between 0 (no re-
sponse) and 100 (strong response) that is calculated from
the heart rate and the pulse-induced volume changes of
the finger (photoplethysmography), which are registered
by a fingertip sensor. Entropy correlates with the depth of
hypnosis [19-21] and was used to adjust the end-tidal
sevoflurane concentration. The electrodermal response
(EDR) is the change in skin conductance in response to a
stimulus and is correlated with the activity of the sympa-
thetic nervous system [22]. A change in skin conductance
occurring after the stimulus was recorded as a sympathetic
response.
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and metabolic data was stopped after the last measurement
following sternal spread.
Pain intensity was assessed with a numeric rating scale
(NRS) from 1 to 10 during the first twenty-four hours in
the intensive care unit by nursing staff blinded to the
patient's group allocation. Opioid analgesic consumption
data were extracted from the patients' charts.
Anesthesia
Anesthesia was induced with sufentanil (150 μg bolus
for patients under 80 kg; 200 μg for patients over 80 kg)
and midazolam (3–6 mg titrated to hypnotic effect).
Rocuronium (1 mg kg−1) was given to facilitate intub-
ation of the trachea. The patients' lungs were ventilated
with 60% oxygen in air in volume-controlled mode with
a tidal volume of 6 ml kg−1 and PEEP 7 cmH2O. The re-
spiratory rate was adjusted to keep end-tidal CO2 be-
tween 35 and 40 mmHg and sevoflurane was added in
an initial age-adapted concentration of 0.5 MAC. The
chosen sevoflurane concentrations were kept constant
by the end-tidal control (ETC.) of the anesthesia ma-
chine (Aisys®, GE Healthcare).
Anesthesia was maintained in both groups with sevoflur-
ane and a continuous infusion of sufentanil (0.017 μg
kg−1 min−1). The end-tidal sevoflurane concentration was
adjusted to keep SE below 60 and the difference between
RE and SE below 10.
A second bolus injection of 50 μg sufentanil was given
ten minutes before sternotomy. Immediately following
the injection the remifentanil infusion was started in the
study group with a 2 μg kg−1 loading dose and an initial
infusion rate of 2 μg kg−1 min−1. The infusion rate was
adjusted in steps of 0.1 μg kg−1 min−1 to keep the SPI
value between 20 and 50. The infusion rate was also in-
creased by 0.1 μg kg−1 min−1 if the SPI value increased
suddenly by more than 10, even if the SPI was still
within the target range. The remifentanil infusion was
continued until the last measurement after sternotomy.
Additional sufentanil was not administered in the con-
trol group because the plasma sufentanil concentrations
were on the upper plateau of the concentration-effect
curve and a further reduction of SPI could not be
achieved with sufentanil.
Mean arterial pressure was kept between 60 and
80 mmHg. We increased the inspiratory sevoflurane
concentration if MAP persisted in any patient at over
80 mmHg. The treatment MAP below 60 mmHg was
based on cardiac index, SVRI and cardiac filling volumes
and consisted of either the administration of dobutamine
or norepinephrine or the infusion of additional fluids.
Bradycardia was defined as a heart rate under 45 beats
per minute and was treated with an infusion of dobuta-
mine if associated with hypotension.Statistical analysis
The data were analyzed with the statistics program Sta-
tistica® (StatSoft Europe). Normal distribution was tested
with the Kolmogorov-Smirnov test. Normally distributed
data were described by mean and standard deviation,
non-parametric data by median and range. Categorical
data were given as percentages. ANOVA was used to test
for changes over time between the groups. Student's t-
test for paired samples was used to pairs of sampling
points in individual groups. Mann–Whitney U-test was
used for non-parametric data and Fisher's exact test for
categorical data. A p-value equal to or less than 0.05 was
considered statistically significant.
The primary end-point of the study was a hemodynamic
response to sternotomy and sternal spread with the re-
sponse defined, as in most similar studies, as a greater
than 15% increase in systolic blood pressure. Secondary
end-points were other indicators of increased sympathetic
nervous system activity, i.e. change in skin conductance,
increased cardiac output, increased systemic vascular re-
sistance and increased oxygen consumption.
For calculating the group size required to give an ad-
equately small Type II error (i.e. adequate statistical
power) we referred to the average published response
rate to sternotomy and sternal spread under high-dose
sufentanil anesthesia in studies that used the same defi-
nitions as employed in the present study; this is approxi-
mately 35%. Two groups with 26 patients each would be
required to detect a reduction of the response rate to
10% with a power of 75% and a statistical significance
level of 5%. We chose to use two groups of 33 patients
each to allow for possible dropouts.
Results
Sixty-six patients were recruited for the study. Four were
excluded from the final analysis because of incomplete
data sets or withdrawn consent (one in study group,
three in control group) (Figure 1: CONSORT flow dia-
gram, Additional file 1). The groups (study group n = 32;
control group n = 30) did not differ with regard to age,
height, body mass index, sex, or ASA classification. All
patients were on chronic medication with beta-blockers
(Table 1).
The infusion rates and doses of anesthetic drugs are
shown in Table 1. The total sufentanil dose administered
from induction to sternotomy was the same in the two
groups.
The SPI increased significantly in both groups during
intubation. The patients in the study group were not re-
ceiving remifentanil at this time. During sternotomy and
sternal spread, SPI increased significantly from 29 to 58
in the control group but did not change in the patients
of the study group, to whom remifentanil was now being
administered. The groups differed significantly at this
Figure 1 CONSORT 2010 flow diagram.
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target range in both groups, but were significantly lower
in the study group after starting the remifentanil infusions.The groups did not differ with regard to the number of
patients who showed a sympathetic response to intubation
(evidenced by the electrodermal response and SPI), which
Table 1 Demographic patient data and dosage and






BMI (kg m−2) 27.3 ± 4.8 28.9 ± 5.0 0.18
Male/Female (n) 19/13 24/6 0.18
ASA I/II/III (n) 0/0/32 0/0/30 1.0
Chronic beta-blocker therapy (n) 32/32 30/30
Remifentanil (maximum infusion rate in μg kg−1 min−1)
before sternotomy 2.0 [0.0 - 6.0] - n.a.
during sternotomy 3.0 [2.0 - 7.0] - n.a.
after sternotomy 2.5 [0.3 - 7.0] - n.a.
Cumulative opioid doses before sternotomy
Sufentanil (μg) 345 ± 68 355 ± 45 0.5
Remifentanil (mg) 6.2 [1.1 - 22.1] - n.a.
(means ± standard deviation, median [range] or count).
n.a. not applicable.







n = 32 n = 30
Systolic arterial pressure (mmHg)
before intubation 108 ± 26 114 ± 19 0.17
after intubation 108 ± 27 115 ± 22 0.25
During surgery before sternotomy 100 ± 17 100 ± 14 0.99
during sternotomy 102 ± 13 115 ± 25 † 0.01
Mean arterial pressure (mmHg)
before intubation 72 ± 15 78 ± 14 0.15
after intubation 74 ± 16 77 ± 14 0.35
During surgery before sternotomy 72 ± 9 76 ± 14 0.2
during sternotomy 70 ± 8 79 ± 13 0.001
Heart rate (min−1)
Before Intubation 61 ± 15 60 ± 14 0.6
After Intubation 61 ± 12 61 ± 13 0.9
During surgery before sternotomy 54 ± 10 53 ± 8 0.9
during sternotomy 54 ± 10 54 ± 10 0.8
Hemodynamic response to sternotomy and sternal spread
Patients with >15% increase in systolic
pressure (n [%])
1 [3%] 6 [20%] 0.035
Average systolic blood pressure change −3.4 ± 8.9 7.5 ± 19 0.005
Average mean arterial pressure change −2.8 ± 8.2 5.9 ± 18 0.02
(means and standard deviation unless otherwise indicated).
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the number of patients with increased sympathetic ner-
vous system activity (evidenced by the electrodermal
response and SPI) in response to sternotomy was signifi-
cantly lower in the study group (Table 2).
The courses of blood pressures and heart rate are
shown in Table 3. Systolic and mean arterial blood pres-
sure increased significantly less in response to sternot-
omy in the remifentanil study group. Sternotomy caused
a greater than 15% increase in systolic blood pressure in
six patients in the control group (20%) and only one
(3%) in the remifentanil group (p = 0.035). Mean arterial
pressure reacted similarly with a 63% response rate in
the control group compared to 38% in the remifentanil











42 ± 14 42 ± 17 0.99
after Intubation 53 ± 14† 58 ± 17† 0.23
During surgery
before sternotomy 35 ± 12 29 ± 18 0.13
during sternotomy 40 ± 15 58 ± 14† <0.001
EDR (n (%))
responders to intubation 12 (36%) 12 (39%) 0.86
responders to sternotomy 12 (37%) 24 (81%) <0.001
(SPI = Surgical Pleth Index; EDR = electrodermal response,
means ± standard deviation).
*Comparison of study vs. control group.
†Comparison before intervention vs. after intervention.Whole body oxygen consumption and systemic vascu-
lar resistance index increased significantly in the control
group. The ejection fraction (fractional area changes) de-
creased significantly in the control group (Table 4).Postoperative pain and opioid analgesic consumption
The median postoperative NRS scores on the day of sur-
gery were 1.5 (range 0–5) in the study group and 2
(range 0–5) in the control group (p = 0.68). On the first
day after surgery they were 2 (range 0–6) in the study
group and 2.5 (range 0–8) in the control group (p = 0.1).
The median postoperative oxycodone consumption
was 3 mg (range 0–26.5 mg) in the study group and
3 mg (range 0 – 19 mg) in the control group on the day
of surgery (p = 0.64). The corresponding doses on the
first day after surgery were 3 mg (range 0 – 23 mg) and
1.5 mg (range 0 – 15 mg) in the study and control
groups, respectively, (p = 0.4).Discussion
The results of this study indicate that high-dose remifenta-
nil given in addition to balanced anesthesia with high-dose
Table 4 Extended hemodynamic monitoring data
Measuring time points
Before sternotomy During sternotomy After sternotomy
Parameter Study Control Study Control Study Control
PAPsyst (mmHg) 29 ± 9 29 ± 7 31 ± 8 33 ± 8 31 ± 6 31 ± 8
PCWP (mmHg) 14 [3–28] 16 [6–26] 13 [6–26] 17 [8–26]* 13 [8–26] 16 [8–25]
CI (l min−1 m−2) 1.5 ± 0.4 1.4 ± 0.3 1.4 ± 0.3 1.5 ± 0.4 1.4 ± 0.3 1.4 ± 0.3
EF (%) 52 ± 12 50 ± 13 52 ± 12 46 ± 13* 51 ± 11 50 ± 13
Δ EF from before to during sternotomy (%) 1.4 ± 10 - 7.6 ± 16†
SVRI 3176 ± 1251 3220 ± 873 3323 ± 1299 3868 ± 1062§ 2918 ± 551 2992 ± 756
VO2 (ml min
−1) 144 ± 25.4 155 ± 41.1 153 ± 34.2 186 ± 49.6* 156 ± 27 173 ± 41.1*
ΔVO2 from before to during sternotomy (%) - 0.4 ± 32 31 ± 46
†
SvO2 78.3 ± 6.6 78.3 ± 5.7 77.7 ± 5.9 78.6 ± 6.7 77.3 ± 9.2 79.0 ± 5.9
(mean ± standard deviation or median [range]).
Abbreviations and symbols: PAPsyst = systolic pulmonary artery pressure; PCWP = pulmonary capillary wedge pressure; CI = cardiac index; EF = left vetricular
ejection fraction; SVRI = systemic vascular resistance index; VO2 = oxygen uptake; SvO2 =mixed venous oxygen saturation.
*p ≤ 0.05; †p < 0.01; ‡p < 0.001 study group vs. control group; §p ≤ 0.05 before vs. during sternotomy (paired t-test).
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blood pressure and sympathetic nervous system activity
induced by sternotomy and sternal spread.
Systolic and mean arterial blood pressures increased
significantly in the control group but not in the study
group. Six patients in the control group (20%) but only
one in the remifentanil study group (3%) had a greater
than 15% increase in systolic blood pressure.
The hemodynamic response rate of 20% in our con-
trol group is similar to that reported by other authors
[5,8,23-25]. Philbin et al. observed hemodynamic re-
sponses rates up to 50% with sufentanil doses between
10 and 40 μg kg−1 body weight [8]. Thompson et al.
using targeted sufentanil plasma concentrations be-
tween 3.0 ± 0.7 ng ml−1 and 7.1 ± 1.3 ng ml−1 found a
greater than 20% increase in mean arterial pressure in
33% to 50% of their patients [24]. These corresponded
to total sufentanil doses of 6.8 ± 1.1 μg kg−1 and 20.9 ±
2.0 μg kg−1, respectively. Ahonen et al. [23] observed a
20% hemodynamic response rate to sternotomy in pa-
tients with a sufentanil plasma concentration of
0.7 ng ml−1. No dose of sufentanil in any of these stud-
ies reduced the response rate to below 20%.
The total sufentanil dose was the same in both groups
and was greater than that necessary to obtain full μ-
receptor occupation and maximum ceiling effect. In our
study, the total sufentanil dose administered during the
study period was approximately 4.3 ± 0.5 μg kg−1, which
corresponds to a plasma concentration in the range of
2 ng ml−1. This is lower than the dose employed in some
studies of the effects of high-dose sufentanil on the re-
sponse to sternotomy [8,24], and one might argue that
one would have obtained the observed effect of remifenta-
nil by simply increasing the sufentanil dose. However, the
results of dose-effect studies and the lack of increasedeffect of high-dose sufentanil contradict this assumption.
The dose–response curve of sufentanil follows the typical
sigmoid curve with a maximum ceiling effect between 1.25
and 1.4 ng ml−1 (see [8,9]). The hemodynamic response
rate to sternotomy in studies was between 20% and 60% in
studies using sufentanil plasma concentrations greater than
this concentration. This ceiling effect concentration is ap-
proximately double the in vitro binding affinity of sufenta-
nil to the μ-opioid receptor [26] and corresponds to a total
dose of approximately 2 μg kg−1 in patients.
Systemic vascular resistance, a parameter also linked to
SNS activity, increased significantly in the control group
during sternotomy and sternal spread. The observed simul-
taneous decrease in ejection fraction is possibly a result of
the increased afterload. Stephan et al. described a similar
response to sternotomy with increased SVR and reduced
cardiac index in patients undergoing myocardial revascu-
larization [27]. This response was not observed in our
study group with remifentanil suggesting that remifentanil
attenuates or suppresses SNS activation.
The electrodermal response (EDR) is the most direct
non-invasive clinical monitor of sympathetic nervous
system (SNS) activity. Increased activity stimulates secre-
tion of eccrine sweat glands with a subsequent change in
skin conductance [22,28,29]. The stimulus of intubation,
which was performed before starting the remifentanil in-
fusion, induced an EDR in an identical number of pa-
tients (responders) in the two groups. Remifentanil
significantly reduced the number of patients with an
electrodermal response to sternotomy and chest spread-
ing by 50% indicating that it suppressed the typical acti-
vation of the SNS.
Increased oxygen uptake is evidence of sympathetic
nervous system activation [30] and our data suggest that
remifentanil suppresses the sympathetic response.
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to quantify sympathetic nervous system activity but
these would have given meaningless results in our study
since many of the patients were receiving catecholamine
infusions for circulatory support during the study period.
These infusions were not responsible for the observed
increase in oxygen consumption, since they were neither
started nor the infusion rate altered in the period before
or during sternotomy.
The inability of sufentanil to reduce the incidence of
hemodynamic responders at doses that would assure a
saturation of μ-opioid receptors suggests that the ob-
served effect of remifentanil is not mediated by μ recep-
tors. Remifentanil has a lower affinity for kappa and
delta opioid receptors, but a considerable degree of re-
ceptor occupation would still have been attained at the
plasma concentrations achieved with the high doses ap-
plied in this study. The binding affinity of remifentanil is
reported to be 2.6 nM for the μ-opioid receptor and 66
nM for the delta receptor [13]. He and Lee showed that
the delta opioid agonist DPDPE acts in a synergistic
fashion to reduce the analgesic ED50 of the μ-receptor
agonist DAMGO even though binding affinity of DPDPE
to delta receptors is at least two orders of magnitude lower
than that of DAMGO to μ receptors [31]. An early study
using specific antagonists of delta opioids receptors (nal-
trindole and naltriben) suggests that sufentanil also has
some affinity to delta receptors to produce respiratory de-
pression [32]. Preconditioning mouse hearts with a remi-
fentanil concentration of 10 nM (=3.8 ng ml−1) was
sufficient to confer cardioprotection and reduce infarct
size. This effect was blocked by naltrindol, a delta-opioid
receptor antagonist [13]. But while a direct effect on the
myocardium might explain the attenuated blood pressure
increase, it would not explain the other observed effects
on sympathetic nervous system activity. Whether the car-
dioprotective effects of remifentanil that were demon-
strated in mice are relevant for cardiac surgery remains to
be determined by further studies.
The depressant effects of remifentanil on hemodynamics
have been shown to be reversed by atropine and are con-
sidered a stimulatory effect of remifentanil on the parasym-
pathetic nervous system [33,34]. These would counteract
sympathetic stimulation, and the hemodynamic effects
of remifentanil observed in the present study could be
attributed to its vagomimetic actions. This hypothesis is
supported by the course of the Surgical Pleth Index
(SPI), which was used to guide the administration of
remifentanil. The SPI is considered to be a measure of
the balance between sympathetic and parasympathetic
nervous system (PNS) activity. High intraoperative
values correlate with stress [35], while lower values in-
dicate a preponderance of PNS over SNS activity. The
remifentanil dose in the study group was increaseduntil the SPI was in an extremely low range corre-
sponding to increased PNS activity.
Some clinicians avoid remifentanil for major surgery
because of their concerns about opioid-induced hyper-
algesia [14,15]. This phenomenon is thought to result
from remifentanil acting at delta-opioid receptors to en-
hance spinal N-methyl-D-aspartate receptor function
[36]. In our study, the reported intensity of postoperative
pain and the amounts of administered analgesics were
the same in the groups with and without remifentanil.
Lahtinen et al. [37] also did not find any evidence of
opioid-induced hyperalgesia following cardiac surgery
when remifentanil was combined with sufentanil.
These findings suggest that remifentanil does not in-
duce clinically relevant hyperalgesia when given for a
short period in combination with sufentanil.
Conclusions
High-dose remifentanil added to balanced high-dose
sufentanil-sevoflurane anesthesia can suppress the ad-
renergic response to sternotomy and sternal spread and
attenuate increases in blood pressure, systemic vascular
resistance and oxygen uptake. In this setting, remifenta-
nil does not induce postoperative hyperalgesia.
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